Citigroup Issues Positive Forecast for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its price objective raised by Citigroup from $9.00 to $10.50 in a research note published on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other analysts also recently issued reports on the company. JPMorgan Chase & Co. upped their price target on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Piper Sandler dropped their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 26th. Evercore ISI raised their target price on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Finally, Stephens reduced their price objective on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Health Catalyst presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.71.

Health Catalyst Price Performance

NASDAQ HCAT opened at $8.66 on Wednesday. Health Catalyst has a 12 month low of $5.42 and a 12 month high of $11.41. The firm has a market capitalization of $526.96 million, a PE ratio of -6.41 and a beta of 1.32. The company’s 50 day simple moving average is $8.13 and its 200 day simple moving average is $7.20. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.22) EPS. As a group, equities research analysts forecast that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling at Health Catalyst

In other news, COO Daniel Lesueur sold 8,137 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the sale, the chief operating officer now owns 140,108 shares in the company, valued at $1,062,018.64. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, COO Daniel Lesueur sold 8,137 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the sale, the chief operating officer now owns 140,108 shares in the company, valued at approximately $1,062,018.64. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the transaction, the insider now directly owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,068 shares of company stock worth $257,555 over the last quarter. 2.50% of the stock is currently owned by insiders.

Institutional Trading of Health Catalyst

Several hedge funds have recently modified their holdings of HCAT. Quest Partners LLC bought a new position in shares of Health Catalyst in the third quarter valued at approximately $34,000. Nisa Investment Advisors LLC lifted its position in shares of Health Catalyst by 461.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after buying an additional 5,232 shares in the last quarter. Quarry LP grew its stake in Health Catalyst by 59.4% in the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after purchasing an additional 2,610 shares during the period. nVerses Capital LLC bought a new stake in shares of Health Catalyst in the 3rd quarter worth approximately $59,000. Finally, Perfromance Wealth Partners LLC bought a new position in Health Catalyst during the second quarter worth about $64,000. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.